Search Results
Jun 29, 2026, 11:49 ET Brayton Purcell LLP Named Finalist for 2026 Trial Lawyer of the Year Award
progressive and fatal lung disease.In recent years, diagnoses have increased, particularly in California, with many individuals affected at relatively young ages. Silicosis results in long-term respiratory impairment, oxygen dependence, and, in severe cases, the need for lung transplantation.Role
More news about: Brayton Purcell LLP
Jun 29, 2026, 09:00 ET TrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and Education
biomarker discovery and precision diagnostics, today announced a commitment to raising awareness of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women. As part of this effort, the company is proud to highlight its partnership with The LAM Foundation, the global
More news about: TrilliumBiO
Jun 29, 2026, 08:45 ET Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
for Canada and other regions included in Eisai's licensed territories.Within the U.K., there are around 50,200 new lung cancer cases every year. Around 80 to 85% of all lung cancers are NSCLC, of which approximately 2% of patients harbor the ROS1+ mutation.The application is based on data
More news about: Nuvation Bio Inc.
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate
More news about: AbbVie
Jun 28, 2026, 22:55 ET 4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.4DMedical's expanding software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the ground-breaking
More news about: 4DMedical
Jun 28, 2026, 22:42 ET 4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.4DMedical's expanding software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the ground-breaking
More news about: 4DMedical
Jun 26, 2026, 09:10 ET Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Jun 26, 2026, 06:31 ET Fractal Appoints Leandro DalleMule as Chief Practice Officer, Financial Services & Insurance
Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal's suite of businesses consists of Asper.ai (a
More news about: Fractal Analytics Limited
Jun 26, 2026, 06:28 ET Fractal Appoints Leandro DalleMule as Chief Practice Officer, Financial Services & Insurance
Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal's suite of businesses consists of Asper.ai (a
More news about: Fractal Analytics Limited
Jun 25, 2026, 10:51 ET Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI
More news about: Racura Oncology Limited
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Jun 25, 2026, 09:00 ET GRAIL Completes $110 Million Equity Financing With Samsung Entities
and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, cervical or lung cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.For more information,
More news about: GRAIL, Inc.
Jun 25, 2026, 08:12 ET IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Jun 25, 2026, 06:11 ET Doctors at HCMCT Manipal Hospital Dwarka perform a life-saving heart bypass and robotic lung cancer surgery in a single session
address the blocked arteries and then carried out a lung cancer surgery using the da Vinci surgical system to remove the cancer-affected part of the lung. The robot-assisted approach provided surgeons with enhanced 3D visualisation and precision during the lung cancer procedure, helping reduce the overall surgical
More news about: Manipal Hospitals, Delhi
Jun 25, 2026, 05:44 ET CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
commercialization rights for sugemalimab in Australia and New Zealand across all approved and future indications, including stage III and IV non-small cell lung cancer (NSCLC), gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and extranodal NK/T-cell lymphoma (ENKTL), subject to regulatory approval
More news about: CStone Pharmaceuticals
Jun 24, 2026, 11:00 ET Parent Project Muscular Dystrophy Hosts 2026 Annual Conference in Orlando, Florida
the lifespan, featuring expert panels on cardiac care, emerging cardiac therapies, advanced therapeutic options, and the connection between heart, lung, and neuromuscular health.Essential elements of care throughout every stage of life, including early childhood, adolescence, and adulthood,
More news about: Parent Project Muscular Dystrophy (PPMD)
Jun 23, 2026, 08:10 ET IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Jun 23, 2026, 07:00 ET Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases—as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and
More news about: Insmed Incorporated
Jun 22, 2026, 17:16 ET Zendure ra mắt hệ sinh thái năng lượng AI ZEN+ HOME tại Intersolar 2026
Zendure là đơn vị tiên phong toàn cầu trong lĩnh vực Hệ thống Quản lý Năng lượng Gia đình (HEMS) dạng cắm có trụ sở tại các trung tâm công nghệ của Thung lũng Silicon, Hoa Kỳ, Khu vực Vịnh Lớn ở Trung Quốc, Nhật Bản và Đức. Sứ mệnh của Zendure là cung cấp nguồn năng lượng sạch, ổn định và giá cả phải chăng
More news about: Zendure
Jun 22, 2026, 14:11 ET Draeger, Inc. Announces FDA Clearance for Evita V800 Software 3.10 - Advancing Ventilation Technology
semi-automated static compliance to assist clinicians in management of inspiratory settings which can potentially reduce the risk of ventilator-induced lung injury (VILI)."Dräger continues to be on the forefront of technology, the addition of these new features for the Evita V800 is another
More news about: Draeger
Jun 22, 2026, 12:19 ET US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12
you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy,
More news about: US WorldMeds